Enhanced neonatal Fc receptor function improves protection against primate SHIV infection-Reference-Cited by-同舟云学术

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

Published:2014-08-13 Issue:7524 Volume:514 Page:642-645
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Ko Sung-Youl,Pegu Amarendra,Rudicell Rebecca S.,Yang Zhi-yong,Joyce M. Gordon,Chen Xuejun,Wang Keyun,Bao Saran,Kraemer Thomas D.,Rath Timo,Zeng Ming,Schmidt Stephen D.,Todd John-Paul,Penzak Scott R.,Saunders Kevin O.,Nason Martha C.,Haase Ashley T.,Rao Srinivas S.,Blumberg Richard S.,Mascola John R.,Nabel Gary J.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature13612.pdf

Reference37 articles.

1. Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nature Rev. Immunol. 7, 715–725 (2007)

2. Ward, E. S. & Ober, R. J. Multitasking by exploitation of intracellular transport functions: the many faces of FcRn. Adv. Immunol. 103, 77–115 (2009)

3. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010)

4. Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101–104 (2007)

5. Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nature Rev. Immunol. 8, 34–47 (2008)

Cited by 326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention;International Immunopharmacology;2024-09

2. PET/CT Targeted Tissue Sampling Reveals Intravenously Administered HGN194 IgG1 Affects HIV Distribution after Rectal Exposure;AIDS Research and Human Retroviruses;2024-08-28

3. Deciphering Fc-effector functions against SARS-CoV-2;Trends in Microbiology;2024-08

4. Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial;BMC Infectious Diseases;2024-07-20

5. Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial Acronym: PedMAb1;2024-07-19